Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period last year.

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begin in 2028.

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

The proposal, purported to save $83 billion over a decade, is a "dagger in the heart of all patient advocacy nonprofits," said the head of a cancer patient support group.

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.

The FDA has offered positive feedback on possible paths forward for accelerated or traditional approval of FLT201 using data from a single-arm study.

The committee recommended the new formulation in two EGFR-mutated advanced NSCLC settings, for which intravenous Rybrevant is already available.

The firm will begin testing a second dose cohort with AMT-191 after receiving a positive recommendation from a data monitoring committee.

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

NEW YORK – Fractyl Health on Friday said it intends to initiate a first-in-human trial of a gene therapy it's developing to treat type 2 diabetes, RJVA-001, in the first half of 2025. Burlington, ...